{"id":9848,"date":"2021-05-17T10:17:48","date_gmt":"2021-05-17T17:17:48","guid":{"rendered":"https:\/\/depts.washington.edu\/pandemicalliance\/?p=9848"},"modified":"2021-05-18T10:18:28","modified_gmt":"2021-05-18T17:18:28","slug":"the-advisory-committee-on-immunization-practices-interim-recommendation-for-use-of-pfizer-biontech-covid-19-vaccine-in-adolescents-aged-12-15-years-united-states-may-2021","status":"publish","type":"post","link":"https:\/\/depts.washington.edu\/pandemicalliance\/2021\/05\/17\/the-advisory-committee-on-immunization-practices-interim-recommendation-for-use-of-pfizer-biontech-covid-19-vaccine-in-adolescents-aged-12-15-years-united-states-may-2021\/","title":{"rendered":"The Advisory Committee on Immunization Practices\u2019 Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine in Adolescents Aged 12\u201315 Years \u2014 United States, May 2021"},"content":{"rendered":"<ul>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">On May 12<\/span><span style=\"font-weight: 400\">th<\/span><span style=\"font-weight: 400\">, 2021, the Advisory Committee on Immunization Practices (ACIP) made an interim recommendation for the use of the Pfizer-BioNTech vaccine among adolescents aged 12-15, following the expansion of the FDA Emergency Use Authorization age eligibility to include this age group. The ACIP considered evidence from a systematic review of published and unpublished evidence of benefits and harms, the importance of COVID-19 as a public health concern, and issues regarding resource use and patients\u2019 and parents\u2019 values and preferences. <\/span><span style=\"font-weight: 400\">Evidence was primarily guided by a randomized, double-blind, placebo-controlled Phase II\/III clinical trial that found 100% efficacy in preventing symptomatic, laboratory-confirmed COVID-19 in adolescents aged 12\u201315 years without evidence of previous SARS-CoV-2 infection.<\/span><\/li>\n<\/ul>\n<p><i><span style=\"font-weight: 400\">Wallace et al.\u00a0(May 14, 2021). The Advisory Committee on Immunization Practices\u2019 Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine in Adolescents Aged 12\u201315 Years \u2014 United States, May 2021. MMWR. Morbidity and Mortality Weekly Report. <\/span><\/i><a href=\"https:\/\/doi.org\/10.15585\/mmwr.mm7020e1\"><span style=\"font-weight: 400\">https:\/\/doi.org\/10.15585\/mmwr.mm7020e1<\/span><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>On May 12th, 2021, the Advisory Committee on Immunization Practices (ACIP) made an interim recommendation for the use of the Pfizer-BioNTech vaccine among adolescents aged 12-15, following the expansion of the FDA Emergency Use Authorization age eligibility to include this age group. The ACIP considered evidence from a systematic review of published and unpublished evidence&#8230;<\/p>\n<div><a class=\"more\" href=\"https:\/\/depts.washington.edu\/pandemicalliance\/2021\/05\/17\/the-advisory-committee-on-immunization-practices-interim-recommendation-for-use-of-pfizer-biontech-covid-19-vaccine-in-adolescents-aged-12-15-years-united-states-may-2021\/\">Read more<\/a><\/div>\n","protected":false},"author":8,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_links_to":"","_links_to_target":""},"categories":[6],"tags":[147],"topic":[31],"class_list":["post-9848","post","type-post","status-publish","format-standard","hentry","category-article-summary","tag-vaccination","topic-vaccines-and-immunity"],"_links":{"self":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/9848","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/comments?post=9848"}],"version-history":[{"count":1,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/9848\/revisions"}],"predecessor-version":[{"id":9849,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/9848\/revisions\/9849"}],"wp:attachment":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/media?parent=9848"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/categories?post=9848"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/tags?post=9848"},{"taxonomy":"topic","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/topic?post=9848"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}